Mumbai, August 29: The Maharashtra Food and Drug Administration (FDA) has taken significant action against a pharmaceutical company. The sales license of Cipla Pharma and Life Sciences Limited, located in Pune, has been revoked in connection with the Reactin Plus tablets case.
According to a press release from the Maharashtra FDA, the Carry and Forwarding (C&F) drug sales license of Cipla Pharma and Life Sciences Limited, situated in Vadki, Pune, was canceled effective August 27, 2026.
The FDA stated that it is conducting regular inspections and strict enforcement actions to ensure the quality, safety, and legal distribution of medicines. This decisive action against the Pune-based company is part of that effort.
The administration reported that an inspection was carried out around June 2026 at the main warehouse of Cipla Pharma and Life Sciences Limited in Vadki, Pune. Serious irregularities were found in the packaging of Reactin Plus tablets during this inspection.
The investigation revealed that Reactin Plus tablets, classified as a Schedule H drug (available only with a doctor’s prescription), had unauthorized claims/advertisements on its packaging stating it was an ‘Analgesic and Antipyretic’ (pain reliever and fever reducer).
This advertisement was found to be in violation of the Drugs and Cosmetics Act of 1940 and the rules of 1945. Consequently, the department seized stock valued at ₹11.19 lakh.
The FDA warned that such advertising could increase the tendency for self-medication among citizens, posing a risk to public health. For this reason, the administration issued directives to the company to recall the misbranded Reactin Plus tablets from the market.
However, the investigation revealed that the company did not fully comply with the necessary actions and the administration’s directives. Following the non-compliance and the discovery of serious irregularities during further investigations, the FDA decided to revoke the company’s C&F license.
The administration has made it clear that similar strict actions will continue against companies that violate regulations to ensure that citizens receive safe and quality medicines.
–
Leave a Comment